Paul L. Weiden

Medicine · Health Sciences

43h-index10.0kcitations126works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(37), Virus-based gene therapy research(25), Radiopharmaceutical Chemistry and Applications(18), Monoclonal and Polyclonal Antibodies Research(16), Veterinary Oncology Research(15)

Publications126 total

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
European Journal of Cancer·2022· 18 citedOpen Access
Agranulocytosis secondary to zinc excess: Clinically relevant observations, including response to G‐CSF and oral copper
Clinical Case Reports·2020· 2 citedOpen Access
Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.
Journal of Clinical Oncology·2014· 22 cited
I Brief Definitive Reports I INFECTIOUS AGAMMAGLOBULINEMIA: TRANSMISSION OF IMMUNODEFICIENCY WITH GRAFTS OF AGAMMAGLOBULINEMIC CELLS
2013
The Art of Medicine: Our Role As Patient Advocates
Journal of Clinical Oncology·2012· 3 cited
Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma
Cancer·2008· 10 cited
Mature results of a phase II study of intraperitoneal topotecan as consolidation therapy in ovarian cancer
Journal of Clinical Oncology·2007
Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with non-small cell lung cancer (NSCLC)
Journal of Clinical Oncology·2004· 4 cited
Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian cancer
Journal of Clinical Oncology·2004· 3 cited
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Blood·2004· 149 citedOpen Access
Pretargeted Radioimmunotherapy (PRIT™) Using an Antibody-Streptavidin Fusion Protein in Non-Hodgkin's Lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2002· 9 cited
Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL)
Critical Reviews in Oncology/Hematology·2001· 76 cited
Cationic Liposome-Mediated<i>E1A</i>Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial
Journal of Clinical Oncology·2001· 209 cited
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
PubMed·2000· 212 cited
Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results
Cancer Biotherapy and Radiopharmaceuticals·2000· 137 cited
Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
PubMed·2000· 151 cited
Interferon Alpha-2a and 13-<i>cis</i>-Retinoic Acid in Patients with Metastatic Renal Cell Cancer
Cancer Investigation·2000· 9 cited
Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: importance of immunocytochemistry.
PubMed·1999· 13 cited
Radiation Absorbed Dose Estimation for <sup>90</sup> Y-DOTA-biotin with Pretargeted NR-LU-10/Streptavidin
Cancer Biotherapy and Radiopharmaceuticals·1999· 67 cited
Factor V leiden mutation does not account for central venous catheter-related thrombosis
American Journal of Hematology·1998· 30 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Rainer Storb(24), E. Donnall Thomas(9), E. Donnall Thomas(8), Hazel B. Breitz(8), George E. Sale(6), Howard M. Shulman(5), Jack W. Singer(5), H. Joachim Deeg(5), K Doney(5), Theodore Graham(5), Keith M. Sullivan(4), Mang-So Tsoi(4), Jean E. Sanders(4), K. G. Lerner(4), CD Buckner(4), Darrell R. Fisher(4), R. Michael Blaese(4), H. Kolb(4), C. Dean Buckner(3), Alexander Fefer(3)